Airborne particles and structural remodeling of the lungs

Particle-Lung Interactions, Second Edition

Volumn , Issue , 2009, Pages 167-192

  Madl, Amy K ^a   Carosino, Christopher ^b   Pinkerton, Kent E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071002170     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (155)

1. Lanza AJ, ed. Silicosis and Asbestosis. New York, NY: Oxford University Press, 1938.
2. Mavrogordato MA. The aetiology of silicosis. 4th Meeting of Permanent International Commission for the Study of Occupational Diseases. Lyon, France, April 3-6, 1929.
3. International Commission on Radiological Protection. Human respiratory tract model for radiological protection. A report of a Task Group of the International Commission on Radiological Protection (ICRP). Ann ICRP 1994; 24(1-3):1-482.
4. Gross P, Tuma J, DeTreville RTP. Lungs of workers exposed to fibreglass. Arch Environ Health 1971; 23:67.
5. Morgan A, Holmes A. Concentrations and dimensions of coated and uncoated asbestos fibres in the human lung. Br J Ind Med 1980; 37:25-32.
6. Timbrell V. Measurement of fibers in human lung tissue. In: Wagner JC, ed. Biological Effects of Mineral Fibers. Lyon, France: International Agency for Research on Cancer (IARC), 1980.
7. Timbrell V. Deposition and retention of fibers in the human lung. Ann Occup Hyg 1982; 26:347.
8. Harris RL Jr., Timbrell V. The influence of fibre shape in lung deposition-mathematical estimates. Inhaled Part 1975; 4(pt 1):75-89.
9. Strom KA, Yu CP. Mathematical modeling of silicon-carbide whisker deposition in the lung-comparison between rats and humans. Aerosol Sci Technol 1994; 24(3):193-209.
10. Sussman R, Cohen B, Lippman M. Asbestos fiber deposition in a human tracheobronchial cast. I. Experimental. Inhal Toxicol 1991; 3(2):145-160.
11. Sussman RG, Cohen BS, Lippmann M. Asbestos fiber deposition in a human trancheo-bronchial cast. Ii. Empirical model. Inhal Toxicol 1991; 3(2):161-179.
12. Yu CP, Zhang L, Oberdorster G, et al. Deposition of refractory ceramic fibers (RCF) from the rat lung-development of a model. Environ Res 1995; 65(2):243-253.
13. Brody AR, Overby LH. Incorporation of tritiated thymidine by epithelial and intersitial cells in bronchiolar-alveolar regions of asbestos-exposed rats. Am J Pathol 1989; 134:133-140.
14. Chang LY, Overby LH, Brody AR, et al. Progressive lung cells reactions and extracellular matrix production after a brief exposure to asbestos. Am J Pathol 1988; 131(1):156-170.
15. McGavran PD, Butterick CJ, Brody AR. Tritiated thymidine incorporation and the development of an interstitial lesion in the bronchiolar-alveolar regions of the lungs of normal and complement deficient mice after inhalation of chrysotile asbestos. J Environ Pathol Toxicol Oncol 1989; 9:377-391.
16. Pinkerton KE, Plopper CG, Mercer RR, et al. Airway branching patterns influence asbestos fiber location and the extent of tissue injury in the pulmonary parenchyma. Lab Invest 1986; 55(6):688-695.
17. Pinkerton KE, Pratt PC, Brody AR, et al. Fiber localization and its relationship to lung reaction in rats after chronic inhalation of chrysotile asbestos. Am J Pathol 1984; 117(3): 484-498.
18. Pinkerton KE, Pratt PC, Crapo JD. Fiber localization within alveolar tissue compartments during and following inhalation of chrysotile. Am Rev Respir Dis 1982; 125(4 part 2):150.
19. Pinkerton KE, Roggli VL, Brody AR, et al. Long-term retention of chrysotile asbestos following acute inhalation. Am Rev Respir Dis 1986; 133(suppl 4):A33.
20. Churg AM, Green FHY. Occupational lung disease. In: Churg AM, Myers JL, Tazelaar HD, et al. eds. Thurlbeck’s Pathology of the Lung. New York: Thieme Medical Publishers, Inc., 2005.
21. Ferin J. Pulmonary tissue access of ultrafine particles. J Aerosol Med 1991; 4(1):57-68.
22. Kreyling WG, Semmler M, Moller W. Dosimetry and toxicology of ultrafine particles. J Aerosol Med 2004; 17(2):140-152.
23. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113(7):823-839.
24. Roth C. Clearance measurements with radioactively labelled ultrafine particles. Ann Occup Hyg 1994; 38:101-106.
25. Roth C. Deposition and clearance of fine particles in the human respiratory tract. Ann Occup Hyg 1997; 40:503-508.
26. Roth C. Clearance of the human lungs for ultrafine particles. J Aerosol Sci 1993; 24: S95-S96.
27. Semmler-Behnke M, Takenaka S, Fertsch S, et al. Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent reentrainment onto airways epithelium. Environ Health Perspect 2007; 115(5):728-733.
28. Collis EL, Gilchrist JC. Effects of dust upon coal trimmers. J Ind Hyg Toxicol 1928; 10: 101-110.
29. Gregory JC. Case of peculiar black infiltration of the whole lungs resembling melanosis. Edinburgh Med Surg J 1831; 36:389-394.
30. Occupational Respiratory Disease Surveillance, NIOSH/DRDS/CWHSP Celebrates the 35th Anniversary of the Federal Coal Mine Health and Safety Act. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH), 2008. Available at: http://www.cdc.gov/niosh/topics/surveillance/ORDS/CoalMineHealthSafetyAct35Years.html.
31. National Institute for Occupational Safety and Health. The Work-Related Lung Disease Surveillance Report, 2002. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (NIOSH), 2003.
32. Castranova V, Vallyathan V. Silicosis and coal workers’ pneumoconiosis. Environ Health Perspect 2000; 108(suppl 4):675-684.
33. Schins RP, Borm PJ. Mechanisms and mediators in coal dust induced toxicity: a review. Ann Occup Hyg 1999; 43:7-33.
34. Shi X, Ding M, Chen F, et al. Reactive oxygen species and molecular mechanism of silica-induced lung injury. J Environ Pathol Toxicol Oncol 2001; 20(suppl 1):85-93.
35. Green FHY. Coal workers’ pneumoconiosis and pneumoconiosis due to other carbonaceous dusts. In: Churg A, Green FHY, eds. Pathology of Occupational Lung Disease. Baltimore: Williams and Wilkins, 1998.
36. Green FHY, Vallyathan V, Brower P, et al. Emphysema in coal workers’ pneumoconiosis: contribution by coal and cigarette smoking. Am Rev Respir Dis 1992; 145:A321.
37. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Ann Rev Med 2003; 54:113-129.
38. Li K, Keeling B, Churg A. Mineral dusts cause elastin and collagen breakdown in the rat lung: a potential mechanism of dust-induced emphysema. Am J Respir Crit Care Med 1996; 153:644-649.
39. Rom WN. Basic mechanisms leading to focal emphysema in coal workers’ pneumoconiosis. Environ Res 1990; 53(1):16-28.
40. Wright JL, Churg A. Animal models of cigarette smoke-induced COPD. Chest 2002; 122(6 suppl):301S-306S.
41. Hunter D, ed. The Pneumoconioses. Boston: Little, Brown & Company, 1969.
42. Air Hygiene Foundation of America Inc. Silicosis and Allied Disorders: History and Industrial Importance. Pittsburgh: Air Hygiene Foundation of America, Inc., 1937.
43. National Institute for Occupational Safety and Health. Health effects of occupational exposure to respirable crystalline silica. Report No. 2002-129. Washington, D.C.: National Institute for Occupational Safety and Health (NIOSH), 2002.
44. NIOSH safety and health topic: Silica. National Institute for Occupational Safety and Health (NIOSH), 2006. Available at: http://www.cdc.gov/niosh/topics/silica/. Accessed October 18, 2006.
45. NIOSH. Silicosis Mortality, Prevention, and Control-United States 1968-2002. Morb Mortal Wkly Rep (MMWR) 2005; 54(16):401-405.
46. Silicosis and Silicate Disease Committee. Diseases associated with exposure to silica and nonfibrous silicate minerals. Silicosis and Silicate Disease Committee. Arch Pathol Lab Med 1988; 112(7):673-720.
47. Blackford JA Jr., Jones W, Dey RD, et al. Comparison of inducible nitric oxide synthase gene expression and lung inflammation following intratracheal instillation of silica, coal, carbonyl iron, or titanium dioxide in rats. J Toxicol Environ Health 1997; 51(3):203-218.
48. Huffman LJ, Judy DJ, Castranova V. Regulation of nitric oxide production by rat alveolar macrophages in response to silica exposure. J Toxicol Environ Health A 1998; 53(1):29-46.
49. Kim JK, Lee WK, Lee EJ, et al. Mechanism of silica- and titanium dioxide-induced cytotoxicity in alveolar macrophages. J Toxicol Environ Health A 1999; 58(7):437-450.
50. Kang JL, Go YH, Hur KC, et al. Silica-induced nuclear factor-kappaB activation: involvement of reactive oxygen species and protein tyrosine kinase activation. J Toxicol Environ Health A 2000; 60(1):27-46.
51. Zeidler P, Hubbs A, Battelli L, et al. Role of inducible nitric oxide synthase-derived nitric oxide in silica-induced pulmonary inflammation and fibrosis. J Toxicol Environ Health A 2004; 67(13):1001-1026.
52. Parks CG, Conrad K, Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect 1999; 107(suppl 5):793-802.
53. Blackford JA Jr., Antonini JM, Castranova V, et al. Intratracheal instillation of silica up-regulates inducible nitric oxide synthase gene expression and increases nitric oxide production in alveolar macrophages and neutrophils. Am J Respir Cell Mol Biol 1994; 11(4):426-431.
54. Vallyathan V, Shi X, Dalal NS, et al. Generation of free radicals from freshly fractured silica dust: potential role in acute silica-induced lung injury. Am Rev Respir Dis 1988; 138 (5):1213-1219.
55. Albrecht C, Knaapen AM, Becker A, et al. The crucial role of particle surface reactivity in respirable quartz-induced reactive oxygen/nitrogen species formation and APE/Ref-1 induction in rat lung. Respir Res 2005; 6:129.
56. Vallyathan V, Mega JF, Shi X, et al. Enhanced generation of free radicals from phagocytes induced by mineral dusts. Am J Respir Cell Mol Biol 1992; 6(4):404-413.
57. Castranova V. Generation of oxygen radicals and mechanisms of injury prevention. Environ Health Perspect 1994; 102(suppl 10):65-68.
58. International Agency for Research on Cancer Working Group. Silica, some silicates, coal dust and para-aramid fibrils. Lyon France: International Agency for Research on Cancer (IARC), 1997.
59. ILSI. The relevance of the rat lung response to particle overload for human risk assessment: a workshop consensus report. International Life Sciences Institute (ILSI) Risk Science Institute Workshop Participants. Inhal Toxicol 2000; 12(1-2):1-17.
60. Daniel LN, Mao Y, Saffiotti U. Oxidative DNA damage by crystalline silica. Free Radic Biol Med 1993; 14(5):463-472.
61. Saffiotti U, Daniel LN, Mao Y, et al. Mechanisms of carcinogenesis by crystalline silica in relation to oxygen radicals. Environ Health Perspect 1994; 102(suppl 10):159-163.
62. Shi X, Mao Y, Daniel LN, et al. Silica radical-induced DNA damage and lipid peroxidation. Environ Health Perspect 1994; 102(suppl 10):149-154.
63. Shi X, Castranova V, Halliwell B, et al. Reactive oxygen species and silica-induced carcinogenesis. J Toxicol Environ Health Part B Crit Rev 1998; 1(3):181-197.
64. Mossman BT, Jimenez LA, BeruBe K, et al. Possible mechanisms of crystalline silica-induced lung disease. Appl Occup Environ Hyg 1995; 10(12):1115-1117.
65. Agency for Toxic Substances and Disease Registry. Toxicological profile for asbestos Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry (ATSDR), 2001.
66. Maines R. Asbestos and Fire: Technological Trade-Offs and the Body at Risk. New Brunswick, NJ: Rutgers University Press, 2005.
67. Roggli VL, Oury TD, Sporn TA, eds. Pathology of Asbestos-Associated Diseases. New York: Springer, 2004.
68. Nicholson WJ, Perkel G, Selikoff IJ. Occupational exposure to asbestos: population at risk and projected mortality, 1980-2030. Am J Ind Med 1982; 3:259-311.
69. Oury TD. Benign asbestos-related pleural disease. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of Asbestos-Associated Diseases. New York, NY: Springer, 2004.
70. Browne K. Asbestos-related disorders. In: Parkes WR, ed. Occupational Lung Disorders. London, England: Butterworth-Heinemann, 1994.
71. Cookson W, de Klerk N, Musk A, et al. The natural history of asbestosis in former cro-cidolite workers in Wittenoom. Am Rev Respir Dis 1986:133; 994-998.
72. Dupres JS, Mustard JF, Uffen RJ. Report of the Royal Commission on Matters of Health and Safety Arising from the Use of Asbestos in Ontario. Toronto, Canada: Queen’s Printer for Ontario, Toronto, 1984.
73. Jacobsson K, Stromberg U, Albin M, et al. Radiological changes in asbestos cement workers. Occup Environ Med 1995; 52:20-27.
74. Weill H. Asbestos cement manufacturing. Ann Occup Hyg 1994; 38:533-538.
75. Churg A, Wright J, Gilks B, et al. Pathogenesis of fibrosis produced by asbestos and manmade mineral fibers: what makes a fiber fibrogenic? Inhal Toxicol 2000; 12(suppl):15-26.
76. Dai J, Churg A. Relationship of fiber surface iron and active oxygen species to expression of procollagen, PDGF-A, and TGF-beta(l) in tracheal explants exposed to amosite asbestos. Am J Respir Cell Mol Biol 2001; 24(4):427-435.
77. Mossman BT, Bignon J, Corn M, et al. Asbestos: scientific developments and implications for public policy. Science 1990; 247(4940):294-301.
78. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157:1660-1680.
79. Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989; 320(26):1721-1730.
80. Mossman BT, Marsh JP. Evidence supporting a role for active oxygen species in asbestos-induced toxicity and lung disease. Environ Health Perspect 1989; 81:91-94.
81. Robledo R, Mossman B. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol 1999; 180(2):158-166.
82. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis in workers exposed to beryllium compounds. J Ind Hyg Toxicol 1946; 28:197-211.
83. Henneberger PK, Goe SK, Miller WE, et al. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg 2004; 1(10):648-659.
84. Sterner JH, Eisenbud M. Epidemiology of beryllium intoxication. Arch Ind Hyg Occup Med 1951; 4:123-151.
85. Deubner D, Kelsh M, Shum M, et al. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl Occup Environ Hyg 2001; 16(5):579-592.
86. Kelleher PC, Martyny JW, Mroz MM, et al. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001; 43(3):238-249.
87. Kent MS, Robins TG, Madl AK. Is total mass or mass of alveolar-deposited airborne particles of beryllium a better predictor of the prevalence of disease? A preliminary study of a beryllium processing facility. Appl Occup Environ Hyg 2001; 16(5):539-558.
88. Kreiss K, Mroz MM, Zhen B, et al. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup Environ Med 1997; 54(8):605-612.
89. Madl AK, Unice K, Brown JL, et al. Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant. J Occup Environ Hyg 2007; 4(6):448-466.
90. Martyny JW, Hoover MD, Mroz MM, et al. Aerosols generated during beryllium machining. J Occup Environ Med 2000; 42(1):8-18.
91. Schuler CR, Kent MS, Deubner DC, et al. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med 2005; 47(3):195-205.
92. Stanton ML, Henneberger PK, Kent MS, et al. Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centers. J Occup Environ Med 2006; 48(2): 204-211.
93. Kreiss K, Day GA, Schuler CR. Beryllium: a modern industrial hazard. Ann Rev Public Health 2007; 28:259-277.
94. Henneberger PK, Cumro D, Deubner DD, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001; 74(3):167-176.
95. 3. Am J Ind Med 1996; 30(1):16-25.
96. Alivisatos P. Colloidal quantum dots. From scaling laws to biological applications. Pure Appl Chem 2000; 72(1-2):3-9.
97. Drexler KE. Nanosystems: Molecular, Machinery, Manufacturing, and Composition. New York, NY: Wiley-Interscience Publication, 1992.
98. Hu JT, Odom TW, Lieber CM. Chemistry and physics in one dimension: synthesis and properties of nanowires and nanotubes. Acc Chem Res 1999, 32(5), 435-445.
99. Lieber C. Nanoscale science and technology: building a big future from small things. MRS Bull 2003; 28(77):486-491.
100. Navrotsky A. Thermochemistry of nanomaterials. Nanopart Environ 2001; 44:73-103.
101. Smalley R. Wires of wonder. Technol Rev 2001; 104(2):86-91.
102. West JL, Halas NJ. Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Ann Rev Biomed Eng 2003; 5:285-292.
103. Hext PM, Tomenson JA, Thompson P. Titanium dioxide: inhalation toxicology and epidemiology. Ann Occup Hyg 2005; 49(6):461-472.
104. Tran CL, Buchanan D, Cullen RT, et al. Inhalation of poorly soluble particles. Ii. Influence of particle surface area on inflammation and clearance. Inhal Toxicol 2000; 12(12):1113-1126.
105. Hext PM. Current perspectives on particulate induced pulmonary tumours. Hum Exp Toxicol 1994; 13(10):700-715.
106. ILSI. The relevance of the rat lung response to particle overload for human risk assessment: a workshop consensus report. ILSI Risk Science Institute Workshop Participants. Inhal Toxicol 2000; 12(1-2):1-17.
107. Ferin J, Oberdorster G. Translocation of particles from the pulmonary alveoli into the interstitium. J Aerosol Med 1992; 5(3):179-187.
108. Ferin J, Oberdorster G, Penney DP. Pulmonary retention of ultrafine and fine particles in rats. Am J Respir Cell Mol Biol 1992; 6(5):535-542.
109. Oberdorster G, Ferin J, Lehnert BE. Correlation between particle size, in vivo particle persistence, and lung injury. Environ Health Perspect 1994; 102(suppl 5):173-179.
110. Sayes CM, Wahi R, Kurian PA, et al. Correlating nanoscale titania structure with toxicity: a cytotoxicity and inflammatory response study with human dermal fibroblasts and human lung epithelial cells. Toxicol Sci 2006; 92(1):174-185.
111. Warheit DB, Webb TR, Reed KL, et al. Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties. Toxicology 2007; 230(1):90-104.
112. Chen HW, Su SF, Chien CT, et al. Titanium dioxide nanoparticles induce emphysema-like lung injury in mice. FASEB J 2006; 20(13):2393-2395.
113. Huczko A, Lange H. Carbon nanotubes: experimental evidence for a null risk of skin irritation and allergy. Fullerene Sci Technol 2001; 9(2):247-250.
114. Huczko A, Lange H, Calko E. Fullerenes: experimental evidence for a null risk of skin irritation and allergy. Fullerene Sci Technol 1999; 7(5):935-939.
115. Huczko A, Lange H, Calko E, et al. Physiological testing of carbon nanotubes: are they asbestos-like? Fullerene Sci Technol 2001; 9(2):251-254.
116. Lam CW, James JT, McCluskey R, et al. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 2004; 77(1):126-134.
117. Muller J, Huaux F, Moreau N, et al. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol Appl Pharmacol 2005; 207(3):221-231.
118. Shvedova AA, Castranova V, Kisin ER, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A 2003; 66(20):1909-1926.
119. Shvedova AA, Kisin ER, Mercer R, et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol 2005; 289(5):L698-L708.
120. Warheit DB, Laurence BR, Reed KL, et al. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci 2004; 77(1):117-125.
121. Dumortier H, Lacotte S, Pastorin G, et al. Functionalized carbon nanotubes are noncytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006; 6(7): 1522-1528.
122. Magrez A, Kasas S, Salicio V, et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett 2006; 6(6):1121-1125.
123. Sayes CM, Marchione AA, Reed KL, et al. Comparative pulmonary toxicity assessments of C60 water suspensions in rats: few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett 2007; 7(8):2399-2406.
124. Tian F, Cui D, Schwarz H, et al. Cytotoxicity of single-wall carbon nanotubes on human fibroblasts. Toxicol In Vitro 2006; 20(7):1202-1212.
125. Shvedova AA, Kisin ER, Murray AR, et al. Vitamin E deficiency enhances pulmonary inflammatory response and oxidative stress induced by single-walled carbon nanotubes in C57BL/6 mice. Toxicol Appl Pharmacol 2007; 221(3):339-348.
126. U.S. Environmental Protection Agency. Air quality criteria for particulate matter. Washington, D.C.: U.S. Environmental Protection Agency (US EPA), EPA 600/P-99/002aF-bF; 2004 October.
127. U.S. Environmental Protection Agency. Provisional assessment of recent studies on particulate matter. Washington, D.C.: U.S. Environmental Protection Agency (US EPA), EPA/600/R-06/063; 2006 October.
128. Dockery DW, Pope CA III, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl J Med 1993; 329(24):1753-1759.
129. Dockery DW. Epidemiologic evidence of cardiovascular effects of particulate air pollution. Environ Health Perspect 2001; 109(suppl 4):483-486.
130. Pope CA IIi. Epidemiology of fine particulate air pollution and human health: biologic mechanisms and who’s at risk? Environ Health Perspect 2000; 108(suppl 4):713-723.
131. Samet JM, Dominici F, Curriero FC, et al. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 2000; 343(24):1742-1749.
132. Pinkerton KE, Green FH, Saiki C, et al. Distribution of particulate matter and tissue remodeling in the human lung. Environ Health Perspect 2000; 108(11):1063-1069.
133. Brook JR, Dann TF. The relationship among TSP, PM10, PM2.5, and inorganic constituents of atmospheric particulate matter at multiple Canadian locations. J Air Waste Manag Assoc 1997; 47:2-19.
134. Churg A, Brauer M, Vedal S, et al. Ambient mineral particles in small airways of the normal human lung. J Environ Med 1999; 1:39-45.
135. Churg A, Brauer M. Human lung parenchyma retains PM2.5. Am J Respir Crit Care Med 1997; 155(6):2109-2111.
136. Churg A, Brauer M, del Carmen Avila-Casado M, et al. Chronic exposure to high levels of particulate air pollution and small airway remodeling. Environ Health Perspect 2003; 111 (5):714-718.
137. Sint T, Donohue JF, Ghio AJ. Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease. Inhal Toxicol 2008; 20(1):25-29.
138. Smith KR, Kim S, Recendez JJ, et al. Airborne particles of the California central valley alter the lungs of healthy adult rats. Environ Health Perspect 2003; 111(7):902-908; discussion A408-A409.
139. Churg A, Wright JL. Bronchiolitis caused by occupational and ambient atmospheric particles. Sem Respir Crit Care Med 2003; 24(5):577-584.
140. Dai J, Xie C, Vincent R, et al. Air pollution particles produce airway wall remodeling in rat tracheal explants. Am J Respir Cell Mol Biol 2003; 29(3 pt 1):352-358.
141. Kooter I, Pennings J, Opperhuizen A, et al. Gene expression pattern in spontaneously hypertensive rats exposed to urban particulate matter (EHC-93). Inhal Toxicol 2005; 17(1): 53-65.
142. Araujo JA, Barajas B, Kleinman M, et al. Ambient particulate pollutants in the ultrafine range promote early atherosclerosis and systemic oxidative stress. Circ Res 2008; 102(5): 589-596.
143. Leong BK, Coombs JK, Sabaitis CP, et al. Quantitative morphometric analysis of pulmonary deposition of aerosol particles inhaled via intratracheal nebulization, intratracheal instillation or nose-only inhalation in rats. J Appl Toxicol 1998; 18(2):149-160.
144. Osier M, Oberdorster G. Intratracheal inhalation vs intratracheal instillation: differences in particle effects. Fundam Appl Toxicol 1997; 40(2):220-227.
145. Rao GV, Tinkle S, Weissman DN, et al. Efficacy of a technique for exposing the mouse lung to particles aspirated from the pharynx. J Toxicol Environ Health A 2003; 66(15): 1441-1452.
146. Driscoll KE, Costa D, Hatch G, et al. Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity; uses and limitations. Toxicol Sci 2000; 55:24-35.
147. Brain JD, Knudson DE, Sorokin SP, et al. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 1976; 11(1):13-33.
148. Oberdorster G, Sharp Z, Atudorei V, et al. Extrapulmonary translocation of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A 2002; 65(20):1531-1543.
149. Henderson RF, Driscoll KE, Harkema JR, et al. A comparison of the inflammatory response of the lung to inhaled versus instilled particles in F344 rats. Fundam Appl Toxicol 1995; 24 (2):183-197.
150. Osier M, Baggs RB, Oberdorster G. Intratracheal instillation versus intratracheal inhalation: influence of cytokines on inflammatory response. Environ Health Perspect 1997; 105(suppl 5):1265-1271.
151. 2 particle formulations: impact of surface treatments on particle toxicity. Toxicol Sci 2005; 88(2):514-524.
152. Oberdorster G, Maynard A, Donaldson K, et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2005; 2:8.
153. Sayes CM, Fortner JD, Guo W, et al. The differential cytotoxicity of water-soluble full-erenes. Nano Lett 2004; 4(10):1881-1887.
154. Veranth JM, Cutler NS, Kaser EG, et al. Effects of cell type and culture media on interleukin-6 secretion in response to environmental particles. Toxicol In Vitro 2008; 22(2): 498-509.
155. Pinkerton KE, Brody AR, Miller FJ, et al. Exposure to low levels of ozone results in enhanced pulmonary retention of inhaled asbestos fibers. Am Rev Respir Dis 1989; 10: 1075-1081.